FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma. Singh S, Bradford D, Chatterjee S, Li X, et al. Clin Cancer Res 2025 Jan 14. doi: 10.1158/1078-0432.CCR-24-3439.

Read + Share

Amedeo Smart

Independent Medical Education

Singh S, Bradford D, Chatterjee S, Li X, et al. FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma. Clin Cancer Res 2025 Jan 14. doi: 10.1158/1078-0432.CCR-24-3439.
PMID: 39808502